Ocugen Sets Sights on Curing Blindness Diseases with Gene Therapies Clinical-stage biopharmaceutical company Ocugen, Inc. is on a mission to develop gene therapies capable of curing blindness diseases. The Pennsylvania-based company's pipeline products reflect its ambitious goals, with candidates like OCU400 poised to revolutionize the treatment of inherited retinal diseases like retinitis pigmentosa and Leber congenital amaurosis. Other products like OCU410 and OCU410ST are aimed at treating dry age-related macular degeneration, while OCU200 is in the preclinical development stage for treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen has also made strategic partnerships to further its mission, including a co-development and manufacturing agreement with CanSino Biologics Inc. for gene therapy, as well as a commercialization deal with Bharat Biotech for COVAXIN in the United States market. As the company works toward its goal of curing blindness diseases, investors will be watching closely for updates on its promising pipeline products.
Ocugen's ticker is OCGN
The company's shares trade on the NASDAQ stock exchange
They are based in Malvern, Pennsylvania
There are 11-50 employees working at Ocugen
It is ocugen.com
Ocugen is in the Healthcare sector
Ocugen is in the Biotechnology industry
The following five companies are Ocugen's industry peers: